Company profile
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States, Canada, and the Netherlands. It operates through two segments, RENB and BioSymetrics. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops BioSymetrics platform, for
- CEO
- Mr. David H. Weinstein
- Headquarters
- Sacramento, CA, United States
- Employees
- 12
- IPO date
- Feb 2, 2015
- Sector
- Healthcare
- Industry
- Biotechnology